Selected article for: "cell host and drug development"
Author: Zhu, Wei; Chen, Catherine Z.; Gorshkov, Kirill; Xu, Miao; Lo, Donald C.; Zheng, Wei
Title: RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery
  • Cord-id: djhnd8kq
  • Document date: 2020_7_13
    • ID: djhnd8kq
    Snippet: COVID-19 respiratory disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has rapidly become a global health issue since it emerged in December 2019. While great global efforts are underway to develop vaccines and to discover or repurpose therapeutic agents for this disease, as of this writing only the nucleoside drug remdesivir has been approved under Emergency Use Authorization to treat COVID-19. The RNA-dependent RNA polymerase (RdRP), a viral enzyme for viral RN
    Document: COVID-19 respiratory disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has rapidly become a global health issue since it emerged in December 2019. While great global efforts are underway to develop vaccines and to discover or repurpose therapeutic agents for this disease, as of this writing only the nucleoside drug remdesivir has been approved under Emergency Use Authorization to treat COVID-19. The RNA-dependent RNA polymerase (RdRP), a viral enzyme for viral RNA replication in host cells, is one of the most intriguing and promising drug targets for SARS-CoV-2 drug development. Because RdRP is a viral enzyme with no host cell homologs, selective SARS-CoV-2 RdRP inhibitors can be developed that have improved potency and fewer off-target effects against human host proteins and thus are safer and more effective therapeutics for treating COVID-19. This review focuses on biochemical enzyme and cell-based assays for RdRPs that could be used in high-throughput screening to discover new and repurposed drugs against SARS-CoV-2.

    Search related documents:
    Co phrase search for related documents
    • acting factor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • action mechanism and adenosine analog: 1, 2
    • action mechanism and adenosine triphosphate: 1, 2
    • active component and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • active component and luciferase expression: 1
    • active compound and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • active form and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
    • active form and adenosine triphosphate: 1, 2, 3, 4, 5
    • active form and low fidelity: 1, 2, 3
    • acute respiratory syndrome and adenosine analog: 1, 2, 3, 4, 5
    • acute respiratory syndrome and adenosine analog monophosphoramidate prodrug: 1
    • acute respiratory syndrome and adenosine triphosphate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and low fidelity: 1, 2, 3, 4
    • acute respiratory syndrome and luciferase expression: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and luciferase rna: 1, 2
    • acute respiratory syndrome and luciferase signal: 1
    • adenosine triphosphate and luciferase signal: 1